Article

Advances in Tardive Dyskinesia: A Review of Recent Literature

In the past three years, the U.S. Food and Drug Administration has approved two medications for tardive dyskinesia, contributing to a resurgent interest in recognition, management, and treatment.

This Psychiatric Times® supplement provides a brief review of primarily recent literature on tardive dyskinesia, including signs and symptoms, risk factors and epidemiology, potential mechanisms, and screening and treatment.

Download Supplement

 

Related Videos
DSM-5-TR Casebook and Treatment Guide for Child Mental Health
rabbit
world peace
Muskin
pigeon city
lithium
social media
ketamine
media
AI
© 2025 MJH Life Sciences

All rights reserved.